Flossbach Von Storch SE Lowers Stock Holdings in Abbott Laboratories $ABT

Key Points

• Flossbach Von Storch SE trimmed its Abbott stake by 2.3% in Q4, selling 152,337 shares and now holds 6,457,646 shares (about 0.37% of ABT) valued at roughly $809 million, making ABT its 12th-largest position and ~3.2% of its portfolio.
• Multiple brokers have reduced price targets recently (e.g., Goldman Sachs to $121, BofA to $120, TD Cowen to $115), yet the stock carries a consensus rating of "Moderate Buy" with an average target of $119.43.
• Abbott slightly beat quarterly estimates (EPS $1.15 vs. $1.14), reported revenue up 7.8% y/y, issued FY2026 guidance of 5.38–5.58 EPS, and declared a $0.63 quarterly dividend (2.7% yield).

Flossbach Von Storch SE lessened its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,457,646 shares of the healthcare product maker's stock after selling 152,337 shares during the period. Abbott Laboratories accounts for approximately 3.2% of Flossbach Von Storch SE's holdings, making the stock its 12th biggest position. Flossbach Von Storch SE owned about 0.37% of Abbott Laboratories worth $809,078,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Wealthstar Advisors LLC lifted its position in shares of Abbott Laboratories by 18.2% in the fourth quarter. Wealthstar Advisors LLC now owns 11,591 shares of the healthcare product maker's stock valued at $1,452,000 after acquiring an additional 1,781 shares in the last quarter. Torren Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $90,000. Rogco LP raised its stake in Abbott Laboratories by 19.0% during the 4th quarter. Rogco LP now owns 2,886 shares of the healthcare product maker's stock valued at $362,000 after purchasing an additional 460 shares during the period. Ares Financial Consulting LLC purchased a new position in Abbott Laboratories in the 4th quarter worth approximately $64,000. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its stake in Abbott Laboratories by 1.3% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 1,077,751 shares of the healthcare product maker's stock worth $135,031,000 after purchasing an additional 14,224 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ABT shares. The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating on the stock in a research report on Wednesday, April 8th. Bank of America cut their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. TD Cowen dropped their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a "buy" rating for the company in a report on Friday, April 17th. Finally, Jefferies Financial Group reduced their target price on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $119.43.

Abbott Laboratories Trading Up 1.9%

Shares of ABT opened at $92.85 on Tuesday. The stock has a market capitalization of $161.71 billion, a PE ratio of 26.01, a P/E/G ratio of 1.52 and a beta of 0.79. The company's fifty day moving average is $105.56 and its 200 day moving average is $116.83. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a fifty-two week low of $90.72 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. During the same period last year, the company posted $1.09 EPS. The business's revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's payout ratio is presently 70.59%.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company's stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the firm's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company's stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last ninety days. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.